Advertisement

Topics

Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition

16:05 EDT 14 Mar 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Multifunctional Bispecific Antibody-Drug Conjugate;Data Scheduled for Presentation at AACR Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today ...

Other Sources for this Article

Zymeworks Inc.
Investor Inquiries:
Ryan Dercho, Ph.D.
(604) 678-1388
ir@zymeworks.com
or
Media Inquiries:
Angela Bitting
(925) 202-6211
a.bitting@comcast.net

NEXT ARTICLE

More From BioPortfolio on "Zymeworks Advances Clinical Candidate Incorporating Technology from Kairos Acquisition"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...